AFT’s Maxigesic IV to be made and sold in China
Listed pharma company signed exclusive licensing deal for intravenous form of its pain relief medicine in world’s second-largest pharma market.
Maxigesic IV will now be sold in nine of the 10 largest pharma markets in the world.
Dual-listed AFT Pharmaceuticals has signed a deal to make and sell the intravenous form of its proprietary pain relief medicine, Maxigesic IV, in China, the largest pharma market in Asia and second-largest in the world.
The deal, the ninth for Maxigesic IV out of the top 10 pharma markets worldwide,
Want to read more? It's easy.
Choose your subscription
Already have an account? Login
Smartphone Only Subscription
NZ$29.95 / monthly
Subscribe Now
Monthly Premium Online Subscription
NZ$49.95 / monthly
Subscribe Now
Smartphone Only Annual Subscription
NZ$299.00 / yearly
Subscribe Now
Yearly Premium Online Subscription
NZ$499.00 / yearly
Subscribe Now
Premium Group Membership 10 Users
NZ$385+GST / monthly
$38.5 per user - Pay by monthly
credit card debit
Subscribe Now
Premium Group Membership 20 Users
NZ$660+GST / monthly
$33 per user - Pay by monthly
credit card debit
Subscribe Now
Premium Group Membership 50 Users
NZ$1375+GST / monthly
$27.5 per user - Pay by monthly
credit card debit
Subscribe Now
Premium Group Membership 100 Users
NZ$2100+GST / monthly
$21 per user - Pay by monthly
credit card debit
Subscribe Now
Yearly Premium Online Subscription + NBR Marketplace
NZ$999.00 / yearly
Subscribe Now
Individual
Group membership
NBR Marketplace
Student
Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
